RITM0291729 Test
The mission of the Metropolitan AntiViral Drug Accelerator (MAVDA) is to conduct innovative, multidisciplinary research to develop, optimize and test innovative small molecule antiviral drugs that target coronaviruses (such as SARS-CoV-2), and other viral families with high potential to cause a pandemic in the future. Our goal is to rapidly develop antiviral drugs that can be given orally in an outpatient setting.
RITM0291729 Test
For more information on AViDD and the program, visit the program’s website. MAVDA is principally located in New York City and New Jersey. It consists of academic and 3 commercial partners.